IXORA-S III期研究:ixekizumab与ustekinumab治疗中重度银屑病24周结果比较
IXORA-S是一项头对头III期研究,比较IL-17A抑制剂ixekizumab与IL-12/23抑制剂ustekinumab治疗中重度银屑病的疗效与安全性。第24周时ixekizumab在PASI、sPGA和DLQI应答率上仍显著更高,安全性特征与既往报告一致。
要点
- 第24周ixekizumab在PASI、sPGA和DLQI应答率上仍显著优于ustekinumab。
- 两组不良事件总体发生率无显著差异,未报告死亡病例。
核心结论
- ixekizumab在中重度银屑病患者中第12周PASI 90应答显著优于ustekinumab,且疗效优势持续至第24周。
- 两种治疗的安全性特征与既往报告一致,总体不良事件发生率无显著差异。
研究设计与样本
- 头对头III期随机对照试验IXORA-S,ixekizumab组n=136,ustekinumab组n=166。
- ixekizumab给药方案:起始160mg,随后80mg每2周一次共12周,之后80mg每4周一次;ustekinumab按标签体重给予45mg或90mg。
- 主要终点为第12周达到PASI 90的患者比例。
临床怎么用
- 对于中重度银屑病需快速强效清除的患者,ixekizumab在PASI 90应答上优于ustekinumab。
- ixekizumab的疗效优势可持续至24周,可作为生物制剂选择的参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It has been shown that the interleukin (IL)-23/IL-17 axis is critical in the pathogenesis of psoriasis. OBJECTIVES: To present the primary end point (week 12) and safety and efficacy data up to week 24 from a head-to-head trial (IXORA-S) of the IL-17A inhibitor ixekizumab (IXE) vs. the IL-12/23 inhibitor ustekinumab (UST). METHODS: Randomized patients received IXE (160-mg starting dose, then 80 mg every 2 weeks for 12 weeks, then 80 mg every 4 weeks, n = 136) or UST (45 mg or 90 mg weight-based dosing per label, n = 166). The primary end point was the proportion of patients reaching ≥ 90% Psoriasis Area and Severity Index improvement (PASI 90). Hommel-adjusted key secondary end points at week 12 included PASI 75, PASI 100, static Physician's Global Assessment (sPGA) score of 0 or 1, sPGA score of 0, Dermatology Life Quality Index (DLQI) score of 0 or 1, ≥ 4-point reduction on the itch numerical rating scale (NRS) and changes in itch NRS and skin pain visual analogue scale. RESULTS: At week 12, IXE (n = 99, 72·8%) was superior to UST (n = 70, 42·2%) in PASI 90 response (response difference 32·1%, 97·5% confidence interval 19·8-44·5%, P < 0·001). Response rates for PASI 75, PASI 100 and sPGA (0,1) were significantly higher for IXE than for UST (adjusted P < 0·05). At week 24, IXE-treated patients had significantly higher response rates than UST-treated patients for PASI, sPGA and DLQI (unadjusted P < 0·05). No deaths were reported, and the treatments did not differ with regard to overall incidences of adverse events (P = 0·299). CONCLUSIONS: The superior efficacy of IXE demonstrated at week 12 persisted up to week 24. The safety profiles were consistent with those previously reported for both treatments.
引用
- Reich K, Pinter A, Lacour JP, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017. PMID: 28542874. doi:10.1111/bjd.15666
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。